Malaysia
Search
Sign In
Change Password
Points
Sign Out
Urology
Top Medical News
Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have rapidly rising levels of prostate-specific antigen (PSA) see radiographic progression of their malignancy even without meeting the criteria set by the Prostate Cancer Working Group 2 (PCWG2), a recent study has shown.
Mirabegron is an effective adjuvant treatment in children with refractory neurogenic bladder, increasing their bladder capacity and helping them achieve continence, a recent study has found.
Commercial antioxidants, such as L‐carnitine and acetyl‐L‐carnitine, increase the quality of sperm in infertile men with high levels of reactive oxidative species at baseline, as shown in a study.
Having a child who undergoes repetitive urological surgeries leads to heightened parental anxiety, a recent study has found. Having an immediate family member who underwent the same surgery is a strong risk factor for parental anxiety.
People who drink alcohol at a high frequency are more likely to develop albuminuria due to their salt intake, a recent study has found. Dietary salt restrictions of these people may have a renoprotective effect.
High genomic score, prostate-specific antigen (PSA) kinetics, and PSA density ≥0.15 are predictive of biopsy reclassification within 3 years of commencing active surveillance, according to a study. Moreover, the association of PSA kinetics and PSA density ≥0.15 with reclassification persists at 5 years following diagnosis.
The investigational combination drug comprising the fourth-generation cephalosporin cefepime and the novel, potent extended-spectrum β-lactamase (ESBL) inhibitor enmetazobactam (FPE) demonstrated superiority to the piperacillin-tazobactam (PTZ) regimen in patients with complicated* urinary tract infection/acute pyelonephritis (cUTI/AP) caused by ESBL-producing Enterobacterales, according to the results of the ALLIUM trial.
Special Reports
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Conference Reports
The investigational combination drug comprising the fourth-generation cephalosporin cefepime and the novel, potent extended-spectrum β-lactamase (ESBL) inhibitor enmetazobactam (FPE) demonstrated superiority to the piperacillin-tazobactam (PTZ) regimen in patients with complicated* urinary tract infection/acute pyelonephritis (cUTI/AP) caused by ESBL-producing Enterobacterales, according to the results of the ALLIUM trial.
The oral prodrug tebipenem pivoxil hydrobromide (TBP-PI-HBr) was as effective as intravenous ertapenem in clearing infection and achieving clinical cure in adult patients hospitalized with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP), shows a head-to-head comparison study, ADAPT-PO.
The SURE*-1 trial demonstrated the potential of a novel, broad-spectrum penem antibiotic – sulopenem etzadroxil/probenecid – for women with uncomplicated urinary tract infection (uUTI).
The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU 2020. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).
The use of sipuleucel-T significantly prolongs overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), regardless of treatment setting, based on real-world data presented at ASCO GU 2020.
A combination therapy of enfortumab vedotin and pembrolizumab shows promising activity, with rapid and durable responses in the first-line setting for patients with metastatic urothelial carcinoma (mUC) ineligible to receive cisplatin, according to updates from the EV-103* study presented at GUCS 2020.
Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU 2020.